Kindred Biosciences EBIT

The latest EBIT for KIN is $-40M as of June 2021. That compares with $-29M in the prior-year period — down 37.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Kindred Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, KIN's EBIT moved from $-29M to $-40M — a 37.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kindred Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, KIN currently prints $-40M for EBIT, while the sector average sits near $23B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Kindred Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-40M for KIN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting KIN's EBIT ($-40M), review year-over-year change from $-29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.